8-K: Hyperliquid Strategies Completes Merger, Pivots to Digital Asset Treasury

Sentiment:

Business Combination Announcement 3 December 2025 8:10 AM

📋All filings for Hyperliquid Strategies INC

Hyperliquid Strategies Inc. has completed its business combination with Sonnet BioTherapeutics and Rorschach I LLC, pivoting to a digital asset treasury model focused on the HYPE token and listing on Nasdaq under 'PURR'.

Capital raiseThe Advisory Agreement states that if the Company raises equity or equity-linked financing during the five-year term, the Advisor will be entitled to receive grants of equity in the form of (a) shares of Common Stock equal to 5% of the number of shares issued or issuable pursuant to such financing and (b) warrants to purchase an aggregate number of shares of Common Stock equal to 15% of the number of shares issued or issuable pursuant to such financing.The ChEF Purchase Agreement with Chardan Capital Markets LLC grants the Company the right to direct Chardan to purchase up to $1.0 billion of Common Stock from time to time, with proceeds intended for general corporate purposes, including HYPE Token purchases.

Summary

Hyperliquid Strategies Inc. (HSI) completed its business combination with Sonnet BioTherapeutics Holdings, Inc. (Sonnet) and Rorschach I LLC on December 2, 2025.
HSI will now operate as a HYPE digital asset treasury reserve company, focusing on maximizing shareholder value through accumulating HYPE, the native token of the Hyperliquid blockchain.
Sonnet and Rorschach I LLC will continue as wholly-owned subsidiaries of HSI.
HSI's common stock is expected to begin trading on The Nasdaq Capital Market under the ticker symbol 'PURR' on December 3, 2025, while Sonnet's common stock will cease trading.
Shares received by former Sonnet shareholders and Rorschach members were adjusted for a five-for-one exchange ratio.
A new Board of Directors was appointed, including Bob Diamond as Chairman and David Schamis as CEO.
Former Sonnet shareholders and Company In-The-Money Warrant holders received Contingent Value Rights (CVRs) tied to 85% of Net Proceeds from the monetization of Sonnet's legacy drug development assets (Company Legacy Assets) over a three-year term.
HSI entered into a Registration Rights Agreement, committing to file a shelf registration statement within 30 days to cover the resale of Registrable Securities held by certain investors and the Advisor.
An Advisor Rights Agreement grants Rorschach Advisors LLC (the Advisor) director nomination rights (including the Chairman) as long as they maintain at least 10% ownership, and an Advisory Agreement outlines technical advisory services related to the digital asset ecosystem for a five-year term.
The Advisor also received warrants exercisable for an aggregate of 27,394,800 shares of Common Stock with varying exercise prices.
The company adopted an amended and restated certificate of incorporation and bylaws, classifying the board into three staggered classes and setting new corporate governance rules.
A 2025 Equity Incentive Plan was approved, reserving 6,351,278 shares of Common Stock for awards.
HSI entered into a ChEF Purchase Agreement with Chardan Capital Markets LLC, allowing HSI to direct Chardan to purchase up to $1.0 billion of Common Stock, with proceeds intended for general corporate purposes, including HYPE Token purchases.

Sentiment

Score: 8

Explanation: The filing announces a significant strategic pivot into a high-growth, high-potential industry (digital assets/DeFi) with a strong underlying platform (Hyperliquid blockchain). The Nasdaq listing, experienced management, and potential for substantial capital raises are strong positives. However, the speculative nature of the CVRs and inherent volatility/regulatory risks of the crypto market temper the overall sentiment, preventing a perfect score.

Positives

The completion of the business combination allows HSI to pivot to a focused digital asset treasury strategy, providing U.S. equity investors direct exposure to the Hyperliquid ecosystem and HYPE token.
The company's common stock will be listed on The Nasdaq Capital Market under the ticker 'PURR', enhancing liquidity and visibility for investors.
The new management team and Board of Directors include highly experienced individuals from finance and digital asset sectors, such as Bob Diamond (Chairman) and David Schamis (CEO), bringing significant industry expertise.
The Hyperliquid blockchain is described as rapidly growing, with its decentralized exchange being a market leader in perpetual futures and spot trading, processing billions in daily trading volume, indicating a strong underlying asset strategy.
The 2025 Equity Incentive Plan reserves 6,351,278 shares of Common Stock, which can be used to attract and retain talent.
The ChEF Purchase Agreement provides a potential source of up to $1.0 billion in capital, which can be used for general corporate purposes, including HYPE Token purchases, supporting the company's core strategy.

Negatives

The Contingent Value Rights (CVRs) issued to former Sonnet shareholders are highly speculative, with no assurance that holders will receive any payments, as payment is contingent on the successful monetization of legacy drug development assets within a three-year term.
CVRs are non-transferable (except in limited circumstances), not certificated, and will not be listed on any exchange, limiting liquidity for CVR holders.
Hyperliquid Strategies Inc. retains 'sole and absolute discretion' over whether to continue investing in the Company Legacy Assets and whether to pursue a Company Legacy Transaction, potentially impacting CVR value.
The company's obligations to use 'Commercially Reasonable Efforts' for Company Legacy Assets are limited by the expenditure of specific financing amounts ($7.5 million in Financings plus up to $3 million in Interim Financing).
The lock-up restrictions on Advisor Shares and Advisor Warrants could limit the immediate liquidity for the Advisor and its affiliates.

Risks

Changes in business, market, financial, political, and regulatory conditions could adversely affect the company's operations.
The highly volatile nature of the price of HYPE tokens poses a significant risk, as HSI's stock price is expected to be highly correlated to HYPE token prices, which may decrease.
Increased competition in the digital asset industries could impact HSI's performance.
Significant legal, commercial, regulatory, and technical uncertainty surrounds HYPE tokens and crypto assets in general.
The tax treatment of crypto assets for U.S. and foreign tax purposes is uncertain and could change, affecting profitability.
HSI may experience difficulties managing its growth and expanding operations, leading to operational challenges.
Challenges in implementing HSI's business plan, including HYPE token-related financial and advisory services, due to operational hurdles, significant competition, and evolving regulation.
The CVRs are highly speculative, and there is no assurance that holders will receive any payments, as the success of Company Legacy Transactions is uncertain and subject to PubCo's discretion and financial limitations.
The company's ability to raise additional capital for Company Legacy Assets is limited to specific financing amounts, and beyond that, it depends on third-party licensing or strategic agreements.

Future Outlook

Hyperliquid Strategies Inc. aims to maximize shareholder value by accumulating HYPE, the native token of the Hyperliquid blockchain, through strategies like staking, yield optimization, and active ecosystem engagement. The company is positioned to become a leading HYPE-focused digital asset treasury vehicle, capitalizing on Hyperliquid's rapid growth and revenue pools. Future equity or equity-linked financings are anticipated, with the Advisor entitled to receive grants of equity and warrants in connection with such raises. The company also has the right to direct Chardan Capital Markets LLC to purchase up to $1.0 billion of Common Stock for general corporate purposes, including HYPE Token purchases.

Management Comments

Bob Diamond, Chairman of HSI, stated: "We are thrilled to have completed this business combination, allowing US equity investors to gain exposure to the HYPE token through our digital asset treasury strategy with a large, highly liquid listing."
David Schamis, CEO of HSI, commented: "The Hyperliquid blockchain was built to house all finance. It has rapidly become one of the highest-revenue-generating blockchains in the world. The Hyperliquid decentralized exchange is a market leader in perpetual futures and spot trading that is used by hundreds of thousands of traders around the world, processing billions in daily trading volume. Today marks a watershed moment: U.S. public market investors can now participate directly in the Hyperliquid ecosystem and do so through a highly liquid, publicly traded vehicle."
Alana Palmedo, Paradigm Managing Partner, noted: "Hyperliquid's approach to high-performance, decentralized trading has attracted substantial volumes from a growing community of traders and developers. Hyperliquid Strategies provides an innovative vehicle for investors to gain exposure to this emerging network."

Industry Context

This announcement signifies a strategic pivot for Hyperliquid Strategies Inc. into the rapidly evolving digital asset ecosystem, specifically focusing on the Hyperliquid blockchain and its native HYPE token. This move aligns with broader industry trends of increasing institutional and public market interest in cryptocurrency and blockchain technologies. By becoming a 'digital asset treasury reserve company,' HSI aims to provide a regulated and publicly traded vehicle for U.S. and institutional investors to gain exposure to a high-performance decentralized finance (DeFi) platform, positioning itself to capitalize on the growth of the Hyperliquid network, which is noted for its market leadership in perpetual futures and spot trading.

Comparison to Industry Standards

The filing highlights Hyperliquid's decentralized exchange as a 'market leader in perpetual futures and spot trading' that processes 'billions in daily trading volume' and is 'used by hundreds of thousands of traders around the world.' This positions Hyperliquid as a significant player in the DeFi and digital asset trading space, suggesting strong performance relative to other decentralized exchanges.
The company aims to provide 'capital-efficient and productive access to the HYPE token for U.S. and institutional investors,' generating 'compounding shareholder returns that individual holders may not be able to replicate through staking, yield optimization, and active ecosystem engagement.' This implies a strategy to offer a more sophisticated and accessible investment vehicle compared to direct individual participation in the crypto market.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Board Member	David Schamis (resigned from initial board)	Bob Diamond	2025-12-02	Election to fill newly-created vacancies as part of business combination, then re-appointed.
Board Member		Jeff Tuder	2025-12-02	Election to fill newly-created vacancies as part of business combination.
Board Member		Eric S. Rosengren	2025-12-02	Election to fill newly-created vacancies as part of business combination.
Board Member		Thomas C. King	2025-12-02	Election to fill newly-created vacancies as part of business combination.
Board Member		Larry Leibowitz	2025-12-02	Election to fill newly-created vacancies as part of business combination.
Board Member	Nailesh Bhatt (Sonnet board)	Nailesh Bhatt	2025-12-02	Election to fill newly-created vacancies as part of business combination.
Board Member	Albert Dyrness (Sonnet board)	Albert Dyrness	2025-12-02	Election to fill newly-created vacancies as part of business combination.
President and Chief Executive Officer		David Schamis	2025-12-02	Continued in role post-merger.
Chief Financial Officer, Secretary and Treasurer		Brett Beldner	2025-12-02	Continued in role post-merger.
Chief Operating Officer		Jeroen Nieuwkoop	2025-12-02	Continued in role post-merger.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Authorized Capital Stock	The Restated Charter authorizes 2,000,000,000 shares of Common Stock and 100,000,000 shares of Preferred Stock.	2025-12-02	Provides significant flexibility for future equity issuances and capital raises.
Board Classification	The Board of Directors is classified into three staggered classes (Class I, II, III), with each class serving three-year terms.	2025-12-02	Staggered board terms can enhance board stability and make hostile takeovers more difficult, potentially reducing accountability to shareholders.
Director Removal Standard	Directors (except Series Directors) can only be removed for cause by the affirmative vote of a majority of the voting power of outstanding capital stock.	2025-12-02	Increases job security for directors and makes it harder for shareholders to remove underperforming directors without a specific 'cause'.
Stockholder Action	Stockholder actions must be effected at a duly called annual or special meeting; actions by written consent in lieu of a meeting are not permitted (except for Preferred Stock).	2025-12-02	Limits shareholder ability to act quickly on important matters without a formal meeting, potentially reducing shareholder activism.
Special Meetings	Special meetings of stockholders can only be called by the Board, Chairperson, CEO, or President.	2025-12-02	Restricts the ability of individual shareholders or groups to call special meetings, centralizing control with management and the board.
Amendment of Charter	Certain provisions of the Restated Charter (Articles V, VI, VII, VIII) require the affirmative vote of at least 66 2/3% of the total voting power of outstanding stock for amendment, alteration, or repeal.	2025-12-02	Establishes supermajority voting requirements for key governance provisions, making them more difficult to change without broad consensus.
Exclusive Forum Provisions	Delaware courts are designated as the exclusive forum for certain internal corporate claims, and federal district courts for Securities Act claims.	2025-12-02	Aims to centralize litigation in specific jurisdictions, potentially reducing legal costs and increasing predictability for the company, but may limit forum choice for plaintiffs.
Series A Preferred Stock Designation	Designated 200,000 shares of Series A Preferred Stock with a $1,000 stated value, convertible into Common Stock at $6.25 per share, subject to a 4.99% (or 9.99%) beneficial ownership blocker. No voting rights except for Fundamental Transactions.	2025-12-02	Provides a mechanism for certain equityholders to hold a significant economic interest with limited immediate voting power, and conversion limitations prevent immediate large-scale dilution or control shifts.
Director Compensation Policy	Approved annual cash compensation of $100,000 ($150,000 for committee chairs), an initial RSU award of $150,000 (3-year vesting), and an annual RSU award of $150,000 (1-year vesting) for non-employee directors.	2025-12-02	Establishes competitive compensation for non-employee directors, aligning their interests with long-term shareholder value through equity awards.

Related Party Transactions

The Advisor Rights Agreement and Strategic Advisor Agreement were entered into with Rorschach Advisors LLC, an entity affiliated with Atlas Merchant Capital LLC and Paradigm Operations LP, which are also sponsors of the business combination. David Schamis, CEO of HSI, is also a Founding Partner and Chief Investment Officer of Atlas Merchant Capital LLC and Manager of Rorschach Advisors LLC. Bob Diamond, Chairman of HSI, is Founding Partner and Chief Executive Officer of Atlas Merchant Capital LLC. Jeff Tuder is an Operating Partner of Atlas Merchant Capital LLC. Thomas C. King and Larry Leibowitz are also Operating Partners of Atlas Merchant Capital.
The Advisor (Rorschach Advisors LLC) received three Advisor Warrants exercisable for an aggregate of 27,394,800 shares of Common Stock.
The Advisor is entitled to receive grants of equity (5% Common Stock, 15% warrants) in future equity or equity-linked financings during the five-year term of the Advisory Agreement.
Rorschach I LLC equityholders received shares of Common Stock (and one received Series A Preferred Stock) in the business combination.

Stakeholder Impact

**Shareholders:** Existing Sonnet shareholders received a combination of HSI Common Stock and CVRs, transitioning their investment from a biotech company to a digital asset treasury company. The CVRs offer potential future value from legacy assets but are highly speculative. New HSI shareholders gain exposure to the HYPE token and the Hyperliquid ecosystem.
**Employees:** The approval of the 2025 Equity Incentive Plan provides a mechanism for attracting and retaining employees through stock-based compensation.
**Customers:** The strategic pivot to a digital asset treasury company implies a shift in focus, potentially impacting former Sonnet customers (if any) and targeting new investors interested in digital assets.
**Creditors:** The ChEF Purchase Agreement provides a potential source of capital, which could improve the company's financial flexibility and ability to meet obligations.
**Management/Directors:** New board members and executive officers are appointed with established compensation structures, aligning their interests with the company's new strategic direction.

Next Steps

Hyperliquid Strategies Inc. common stock is expected to begin trading on The Nasdaq Capital Market under the ticker symbol 'PURR' on Wednesday, December 3, 2025.
The Company will file a shelf registration statement within 30 calendar days following the Closing Date to cover the public resale of Registrable Securities.
The financial statements of Sonnet BioTherapeutics Holdings, Inc. and unaudited pro forma financial information required by Item 9.01(a) and (b) of Form 8-K will be filed by an amendment to this Current Report no later than 71 days after the due date of this Current Report.

Key Dates

Date	Description
2025-07-11	Date of the original Business Combination Agreement.
2025-09-22	Date of Amendment No. 1 to the Business Combination Agreement.
2025-10-22	Date of the ChEF Purchase Agreement and the Chardan Registration Rights Agreement.
2025-10-27	Date of filing of the S-4/A prospectus/proxy statement by HSI.
2025-11-10	Effective date of the registration statement on Form S-1 covering shares issuable pursuant to the ChEF Purchase Agreement.
2025-12-02	Closing Date of the business combination; Sonnet stockholders approved the 2025 Equity Incentive Plan; Advisor Rights Agreement, Strategic Advisor Agreement, Contingent Value Rights Agreement, and Registration Rights Agreement were entered into; new Board of Directors and executive officers became effective; amended and restated certificate of incorporation and bylaws adopted.
2025-12-03	Expected date for Hyperliquid Strategies Inc. common stock to begin trading on The Nasdaq Capital Market under the symbol 'PURR'.

Keywords

Hyperliquid, HYPE token, digital assets, blockchain, merger, business combination, Nasdaq, PURR, Rorschach, Sonnet, contingent value rights, registration rights, corporate governance, equity incentive plan, Chardan Capital Markets

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.